Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

PRO: A Deeper Dive Into GH Research

May 11 • 1 min read

In our latest PRO episode, Adam Tubero digs into GH Research ($GHRS).

Psychedelic Stock Market Update | April 2022

May 4 • 4 min read

In our last stock market update in January we mentioned that “the past few months haven’t been kind to psychedelic investors.” Well, it’s three months later and from a price perspective we can’t say much has changed. With that being said, there are some exciting stories at play which we will get to below, but…

PRO: Last Week in Review – Field Trip, Oregon, Psilocybin, and More

May 2 • 1 min read

In our latest episode, Adam Tubero digs into last week’s Field Trip news, Oregon’ legalization of psilocybin, and a breakdown of natural versus synthetic psilocybin.

PRO: A Deeper Dive Into Cybin (CYBN)

Apr 22 • 1 min read

In our latest episode, Adam Tubero digs into one of the more well-known Psychedelic biotech companies in the industry, Cybin (CYBN). Tune in as we take a closer look at Cybin’s financials, the development of CYB003 – which has the potential to effectively treat major depressive disorder (MDD) and alcohol use disorder (AUD) – and…

PRO: A Deeper Dive Into ATAI’s Strategic Partnership With IntelGenX

Apr 21 • 1 min read

In March, IntelGenx Technologies Corp. (IGX) announced that its wholly-owned subsidiary, IntelGenx Corp, has agreed to a strategic partnership with atai Life Sciences (ATAI), one of the industry’s largest clinical-stage biopharmaceutical companies aiming to transform the treatment of mental health disorders. In connection with this partnership, atai acquired ~25% of IntelGenx for approximately $12.3 million…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354